What is the recommended intravenous ascorbic acid infusion rate and total dose for an adult with normal renal function and no contraindications?

IV Vitamin C Infusion Rate and Dosing

For adults with normal renal function receiving IV vitamin C, infuse doses of 1-3 grams diluted in 50-250 mL normal saline or dextrose solution over 30-60 minutes, with higher doses (>3 grams) requiring slower infusion over 1-2 hours to minimize adverse reactions. 1

Standard Infusion Protocols by Clinical Indication

Critical Illness and Acute Inflammation

• Administer 2-3 g/day IV during the acute inflammatory phase (Grade B recommendation, 84% consensus) 2, 1
• This higher repletion dose is necessary because plasma vitamin C concentrations decline rapidly when C-reactive protein exceeds 10 mg/L 2, 1
• IV administration is essential in critically ill patients due to unpredictable enteral absorption from impaired gut function and limited intestinal transporter capacity 1

Continuous Renal Replacement Therapy (CRRT)

• Use 2-3 g/day IV for patients on CRRT 2, 1
• Higher doses compensate for increased clearance through dialysis circuits

Perioperative Cardiac Surgery

• Administer 1-2 g/day IV for 5-7 days perioperatively 2, 1
• This dosing supports wound healing and reduces oxidative stress from surgical trauma

Severe Sepsis Protocols

• Some protocols use 200 mg/kg/day for 4 days in severe sepsis and acute respiratory failure 1
• For a 70 kg adult, this equals approximately 14 g/day divided into multiple doses

Infusion Rate Guidelines

Preparation and Dilution

• Dilute vitamin C with normal saline or glucose solution before IV administration to minimize adverse reactions 1
• For doses of 1-3 grams: dilute in 50-100 mL and infuse over 30-60 minutes
• For doses >3 grams: dilute in 250 mL and infuse over 1-2 hours 3

Rate Considerations

• Slower infusion rates reduce the risk of dose-related adverse effects including hypotension and osmotic effects 3
• Rapid bolus administration should be avoided; controlled infusion allows for monitoring and early detection of adverse reactions

Pharmacokinetic Rationale

Why IV Administration Achieves Therapeutic Levels

• Oral vitamin C produces tightly controlled plasma concentrations that never exceed 220 μmol/L even with maximum tolerated oral doses of 3 g every 4 hours 4, 5
• IV administration bypasses intestinal absorption limits and can achieve pharmacologic concentrations of 25-30 mmol/L (25,000-30,000 μmol/L) 5
• A 50-g IV dose produces predicted peak plasma concentrations of 13,400 μmol/L compared to only 220 μmol/L from maximum oral dosing 4

Duration of Elevated Levels

• Pharmacologic ascorbate concentrations are maintained until excess is eliminated by glomerular filtration and renal excretion 5
• The biological half-life at high plasma levels is approximately 30 minutes, requiring sustained or repeated dosing 6

Monitoring and Safety

When NOT to Measure Plasma Levels

• Do not measure plasma vitamin C during critical illness or severe inflammation (Grade GPP, 92% consensus) 2, 1
• Blood levels become undetectable when CRP >40 mg/L, making interpretation impossible 2, 1
• Plasma levels decline as soon as CRP >10 mg/L 2, 1

When Measurement May Be Useful

• Consider measuring plasma vitamin C only in patients with suspected scurvy or chronic low intake in the absence of acute inflammation 2, 1

Clinical Monitoring

• Monitor blood pressure during infusion, as rapid administration can cause transient hypotension 3
• Observe for signs of fluid overload in patients with cardiac or renal compromise 7
• Clinical response (wound healing, resolution of symptoms) is more practical than laboratory monitoring during inflammatory states 8

Absolute Contraindications and Dose Limits

Maximum Safe Dosing

• Do not exceed 2-3 g/day in patients with renal impairment, history of kidney stones, or on CRRT due to risk of fatal nephrotoxicity 2
• The tolerable upper level is 2 g/day based on gastrointestinal upset; higher doses may cause severe diarrhea and increase oxalate absorption 2

Specific Contraindications

• Avoid in patients with hemochromatosis or iron overload as vitamin C enhances iron absorption 8
• Avoid in G6PD deficiency when using vitamin C as treatment for methemoglobinemia, though this is a specific therapeutic context 9
• Use caution in pregnant women due to theoretical teratogenicity concerns 9

Duration of Therapy

Acute Phase Treatment

• Continue IV vitamin C for 4-7 days during the acute phase of critical illness 2
• For wound healing after major surgery or amputation, continue throughout the acute healing phase (approximately 2-4 weeks) or until adequate healing is achieved 8

Transition to Maintenance

• Sustained therapy is needed to prevent recurrence of hypovitaminosis 1, 8
• Once enteral function is restored, transition to oral supplementation at 200-500 mg/day for maintenance 2, 8

Common Pitfalls to Avoid

Inadequate Dosing in Inflammation

• Do not use standard RDA doses (75-90 mg/day) during critical illness—these are insufficient to restore plasma concentrations in inflammatory states 2, 10
• Shocked surgical, trauma, and septic patients require 3 g/day to restore normal plasma ascorbate concentrations, far exceeding the recommended PN dose of 100 mg/day 10

Route of Administration Errors

• Do not rely on oral dosing to achieve therapeutic levels in critical illness—intestinal absorption is saturated and unpredictable 1, 4
• Oral vitamin C at 1.25 g produces peak plasma concentrations of only 135 μmol/L versus 885 μmol/L for the same IV dose 4

Infusion Rate Mistakes

• Avoid rapid bolus injection of doses >100 mg to minimize arthralgias, myalgias, and hypotension 3
• Do not infuse >125 mg of certain formulations (e.g., iron gluconate preparations) as a bolus 3

Patient-Specific Factors Affecting Response

• Cancer patients with high tumor burden or inflammation achieve lower post-infusion plasma levels despite identical dosing 11
• Patients deficient in vitamin C prior to therapy tend to achieve lower plasma levels post-infusion 11
• Metastatic disease lowers peak plasma ascorbate concentrations compared to localized tumors 11